Preclinical animal testing is used to give reasonable data prior to early feasibility testing in people and human clinical trials in order to show that new technologies and therapies are safe and effective. During the nonclinical phase, animal models can help support and develop medical product development. Animal models that are well-designed can solve regulatory safety issues and provide further de-risking during product validation. Animal models can be used to evaluate minimum viable products and prototypes, which can help with quality assurance and compliance. To avoid superfluous preclinical research, a roadmap for product innovation strategies (regulatory, reimbursement) must be developed. Preclinical animal model safety and efficacy data are an important aspect of medical device development and are required to make these judgments. Before moving on to costly human trials, this can assist evaluate if the gadget is effectively tackling an actual need. Academic centers, which are generally based in linked veterinary medicine schools, provide unique resources that might help academic entrepreneurs fill this preclinical need.
Title : 30,000 nano implants in humans with no infections, no loosening, and no failures
Thomas J Webster, Interstellar Therapeutics, United States
Title : Comparison of the clinical efficacy of platelet-rich plasma and artificial dermis in the treatment of fingertip defects
Haidong Liang, The Second Affiliated Hospital of Dalian Medical University, China
Title : Integrating planar and non-planar layers for optimized bioprinted scaffold structures with controlled porosity
Laura Perez Sanchez, Vicomtech Foundation, Spain
Title : Potential of articular cartilage resident progenitor in the field of cartilage regeneration
Elizabeth Vinod, Christian Medical College, India
Title : Connections between modern physics and practice regenerative medicine
Marco Polettini, DVM, Italy
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model to secure the human healthcare, wellness and biosafety: Through the view of cell-based therapy and rehabilitation
Sergey Suchkov, The Russian University of Medicine and The Russian Academy of Natural Sciences, Russian Federation